BioIntelliSense, Inc., a Denver, CO-based continuous health monitoring and clinical intelligence company, closed a $45 million Series B financing round.
The round was led by Chimera (UAE), which was joined by 7wire Technology Partners, Mary Tolan of Chicago Pacific Founders, James Murren formerly of MGM Resorts International, as well as Pendrell Corporation, Royal Philips, and Fresenius Medical Care North America. These parties joined the existing investors from the Series A financing, namely TripleTree Holdings, UCHealth and the CU Healthcare Innovation Fund.
The company intends to use the funds for continued growth and global expansion of its medical grade wearable devices and advanced data services for scalable remote care.
Led by James Mault, MD, CEO, BioIntelliSense provides continuous health monitoring and clinical intelligence for Remote Patient Monitoring (RPM). Its medical-grade Data-as-a-Service (DaaS) platform captures multi-parameter vital signs, physiological biometrics, and symptomatic events through an easy patient experience. In addition, the company’s FDA-cleared BioSticker™ and medical-grade BioButton® devices enable simple remote monitoring and early detection. Through the platform’s advanced analytics, clinicians have access to high-resolution patient trending and reporting to enable medical grade care at home.